The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camrelizumab in combination with fluorouracil or taxol plus platinum chemotherapy as first-line treatment of esophageal squamous cell carcinoma: A multicenter, open-label, prospective cohort study.
 
Jun Zhao
No Relationships to Disclose
 
Wenqing Hu
No Relationships to Disclose
 
Xiaoling Zhang
No Relationships to Disclose
 
Yunyi Du
No Relationships to Disclose
 
Chunmei Yao
No Relationships to Disclose
 
Ning Ma
No Relationships to Disclose
 
Wei Yang
No Relationships to Disclose
 
Bo Yang
No Relationships to Disclose
 
Yudong Xue
No Relationships to Disclose
 
Yangjun Gao
No Relationships to Disclose
 
Yu Wang
No Relationships to Disclose
 
Min Liu
No Relationships to Disclose
 
Mei Wang
No Relationships to Disclose
 
Hui Wang
No Relationships to Disclose
 
Tingting Feng
No Relationships to Disclose
 
Linlin Cai
No Relationships to Disclose
 
Cuihua Zhang
No Relationships to Disclose
 
Kai Ma
No Relationships to Disclose
 
Ning Xu
No Relationships to Disclose
 
Jing Lu
No Relationships to Disclose